When faced with patients suffering a heart attack, doctors have two choices: fibrinolytic therapy or primary percutaneous coronary intervention. Guidelines for treating heart attacks are generally based on clinical trials that do not take “real-life” conditions into account. The latest study analyzes these gaps and provides potential solutions to improve treatment of heart attack.